The shadow of generic rivalry has long loomed above copyright’s iconic drug, Viagra, triggering questions about the future of Pharma connected medicinal ventures. While first years saw substantial returns, the patent lapse has opened the path for cheaper substitutes, possibly reducing revenue and presenting a genuine risk for shareholders pursuin